India, July 25 -- Shares of NextCure Inc. (NXTC) are up nearly 30% at $6.60 in premarket trading on Friday, following encouraging preclinical data of its brittle bone disease drug candidate, NC605.
Osteogenesis imperfecta (OI), or brittle bone disease, is a rare disorder that results in high bone turnover, abnormal bone formation, bone fragility, and recurrent fractures. There is no cure for OI.
According to the results announced today, NC605, a novel anti-Siglec-15 antibody, achieved improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment in a well-established mouse model of osteogenesis imperfecta. NC605 has been shown to inhibit bone loss and to produce new bone, with increased quality and d...